Clinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification

Seminoma accounts for 30-50% of testicular germ cell tumors (TGCT)-the most common solid malignancy in men aged 15-35 years. The American Joint Committee on Cancer (AJCC) 8th edition (2018) created the subclassifications pT1a (tumor size 4 cm are considered features associated with a higher recurre...

Full description

Saved in:

Bibliographic Details
Published in:	BMC urology 2020-08, Vol.20 (1), p.127-127, Article 127
Main Authors:	Fontes-Sousa, Mário, Lobo, João, Magalhães, Helena, Cassis, João, Malheiro, Mariana, Ramos, Sância, Henrique, Rui, Martins, Ana, Maurício, Maria Joaquina
Format:	Article
Language:	eng
Subjects:	Adjuvant chemotherapy Adolescent Adult Aged AJCC Biomarkers Cancer Cancer staging Chemotherapy Clinical medicine Germ cell tumors Histology Humans Male Malignancy Medical prognosis Middle Aged Neoplasm Staging Pathology Patients Radiation therapy Radiotherapy Rete testis Retrospective Studies Seminoma Seminoma - classification Seminoma - pathology Surveillance Testicular cancer Testicular Neoplasms - classification Testicular Neoplasms - pathology Tumors United States Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Seminoma accounts for 30-50% of testicular germ cell tumors (TGCT)-the most common solid malignancy in men aged 15-35 years. The American Joint Committee on Cancer (AJCC) 8th edition (2018) created the subclassifications pT1a (tumor size 4 cm are considered features associated with a higher recurrence risk, but not formally used for staging. The authors propose further understanding the subclassification's potential impact in clinical practice, by summarizing current evidence and reviewing clinical cases in their institutions. All consecutive cases of seminoma stage I, pT1 treated in two institutions between January 2005 and December 2016 were included. Clinical data were retrieved, and variables were analyzed using SPSS. Relevant literature on the topic was reviewed. Seminoma pT1 was identified in 58 patients. By using newly AJCC criteria, 29 (50%) would have been staged as pT1a and 29 (50%) pT1b. Median age at diagnosis was similar (33 in pT1a vs 32 in pT1b). Median follow-up time 5.8 years. Almost half (45%) of pT1b patients had a tumor size
ISSN:	1471-2490 1471-2490